Gyre Therapeutics CEO Outlines China Cash Flow Pipeline Strategy

Gyre Therapeutics is leveraging its profitable commercial operations in China to self-fund its early-stage protein degradation research, extending its operational runway without relying entirely on external equity financing, according to company executives.

“Our wet labs are all in China, but all of the research innovations are within San Diego, the Delaware company. Then with the commercialization arm, we can utilize our cash flow generated in China to fund our research. This has significantly extended our cash runway and also gave us early commercialization possibility,” said Ying Luo, CEO, Gyre Therapeutics, during the Morgan Stanley 24th Annual Global Healthcare Conference.

Corporate Structure and Dual-Region Operations

The current operational footprint of Gyre Therapeutics is the result of a deliberate corporate combination intended to span the entire pharmaceutical value chain.

“Gyre is formed through a combination of the previous Gyre and the new Cullgen. We combined them together and form today’s Gyre Therapeutics because, in this way, we can cover from discovery all the way to commercialization,” said Ying Luo, CEO, Gyre Therapeutics.

This cross-border structure pairs early-stage discovery operations based in San Diego with established manufacturing and sales infrastructure in Asia. Protein degradation represents a complex therapeutic modality focused on hijacking the body's natural cellular machinery to destroy disease-causing proteins rather than simply inhibiting them.

Commercial Portfolio and Pending Approvals

The funding model relies on the commercial success of the company's approved medications. Gyre's lung fibrosis drug ETUARY received initial approval in 2011 and maintains a position as a top-tier pirfenidone product globally.

Building on this established revenue base, the company is advancing a new drug application in China for hepatitis B virus (HBV)-associated liver fibrosis. This pending regulatory submission targets an addressable patient population estimated between 15 million and 30 million individuals in the region.

Market Valuation and Trading Data

In the public markets, Gyre Therapeutics (GYRE) traded at $7.55, marking a 5.15% increase from its previous close of $7.18, as of 2026-09-18, according to Finnhub market data.

What Cross-Border Funding Means for Biotech

For clinical-stage biotechnology firms, maintaining cash runway is a central operational challenge that typically requires dilutive secondary share offerings or high-cost debt facilities. By utilizing regional commercial revenue streams to absorb early-stage research and development expenditures, Gyre Therapeutics illustrates an alternative funding mechanism designed to sustain long-term drug discovery programs independently.